AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01734213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriobotyra Japonica Lindley Extract
Description: Eriobotyra Japonica Lindley Extract (1.5g/day)
Study NCT01734213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.5g/day)
Study NCT04446117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied as 20-mg tablets; administered orally daily at 40mg
Study NCT04446117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
Study NCT04446117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
Study NCT04446117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Supplied as 40 mg capsules; administered orally daily at 160mg
Study NCT04446117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
Study NCT03531593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Elastography
Description: Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
Study NCT03189914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-3117
Description: RX-3117 will be administered orally in combination with Abraxane.
Study NCT03505658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Behavior
Description: Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
Study NCT02044887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
Study NCT00815126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lysine-ASA Nasal ProvocationTest
Description: Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
Study NCT00483522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management telephone counseling
Description: Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
Study NCT01427244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: monoclonal antibody
Study NCT01621373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol administration
Description: Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
Study NCT03319043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chanqin granules
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
Study NCT03319043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chanqin granules
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
Study NCT03058731 — intervention group
Intervention type: DEVICE
Intervention: Matristem
Description: Paraesophageal hernia repair with MatriStem Surgical Matrix
Study NCT03058731 — intervention group
Intervention type: DEVICE
Intervention: Control
Description: Paraesophageal hernia repair with other biologic mesh
Study NCT05095480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice Pill
Description: Taking Lesstat
Study NCT05095480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo receiving group
Study NCT01933334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
Study NCT02182544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL801CL dry syrup
Study NCT02182544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen fumarate dry syrup
Study NCT02182544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate dry syrup placebo
Study NCT02182544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WAL 801 CL dry syrup placebo
Study NCT04962971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: X
Description: exocyan
Study NCT04962971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Y
Description: exocyan
Study NCT04962971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Z
Description: exocyan
Study NCT02530619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT03456778 — intervention group
Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
Study NCT02530619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01097226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple extract delivering 70 mg epicatechin
Description: Delivered as a flavoured water based beverage
Study NCT01097226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple extract delivering 140 mg epicatechin
Description: Delivered as a flavoured water based beverage
Study NCT01097226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple granules delivering 70 mg epicatechin
Description: Delivered as a puree
Study NCT01097226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water delivering no epicatechin
Description: Delivered as flavoured water
Study NCT03185624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Antibiotics
Study NCT01699997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal spray with 40 IU of OXT
Study NCT01699997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal spray with placebo solution
Study NCT03021759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
Study NCT03021759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social comparison feedback
Description: Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
Study NCT00710333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
Study NCT00710333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02517346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
Study NCT02517346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Follow up by telemonitoring system during 3 months
Study NCT04089644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop system
Description: Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)
Study NCT04089644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual adjustment
Description: Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)
Study NCT00014144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT04441203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMems
Description: novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
Study NCT02325401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
Study NCT02325401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dosed at 100mg/m2 on days 1, 22, and 43
Study NCT02325401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70 Gy in 2 Gy once daily fractions of 35 fractions
Study NCT00753324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine three-drug antiretroviral prophylaxis
Description: Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
Study NCT02011841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: rifaximin 1200 mg/day orally for 6 months
Study NCT02011841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: ciprofloxacin 500 mg/day orally for 6 months
Study NCT00058890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
Study NCT00058890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04359836 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in this study
Description: There is no intervention in this study
Study NCT04188041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TB Infection ECHO
Description: A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 90 mg QD
Description: given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 120 mg QD
Description: given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
Study NCT00844194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
Study NCT03396744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
Study NCT02560129 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, Physical and Cognitive Function
Description: ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
Study NCT04174274 — intervention group
Intervention type: OTHER
Intervention: ventilator-associated pneumonia-developed group followed by mechanical ventilation
Description: compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
Study NCT04174274 — intervention group
Intervention type: OTHER
Intervention: not ventilator-associated pneumonia-developed group followed by mechanical ventilation
Description: compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
Study NCT01719965 — intervention group
Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions
Study NCT00803023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: 4.5 grams per night taken in two equally divided doses
Study NCT00803023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate & 6 Tablets
Description: 4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
Study NCT00803023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate & 8 Tablets
Description: 6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
Study NCT00803023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate Oral Solution (6 grams)
Description: 6 grams per night taken in two equally divided doses
Study NCT04575779 — intervention group
Intervention type: DRUG
Intervention: Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
Description: To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
Study NCT03404024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stage 1-Low dose VM202RY
Description: Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
Study NCT03404024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stage 1-Middle dose VM202RY
Description: Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
Study NCT03404024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stage 1-High dose VM202RY
Description: Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
Study NCT03404024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stage 2-Placebo
Description: Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
Study NCT03404024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stage 2-Low dose VM202RY
Description: Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
Study NCT03404024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stage 2-High dose VM202RY
Description: Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
Study NCT03404024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Cathez® Catheter
Description: Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
Study NCT04623619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetyl L-Carnitine
Description: Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
Study NCT03404024 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C-Cathez® Catheter
Description: Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
Study NCT01542528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBS
Description: Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
Study NCT01462734 — intervention group
Intervention type: PROCEDURE
Intervention: human vitreous and blood serum sampling, PCR
Description: 1ml of human vitreous and 3ml of human blood serum
Study NCT02760186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Altitude Exposure
Description: Altitude Exposure
Study NCT02591394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP Clinic
Description: Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
Study NCT02591394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers.
Study NCT01910844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
Study NCT01910844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
Study NCT04043052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;